1,4,5,8-tetrahydro-1,4:5,8-dimethanoanthracene-9,10-bis(methylphosphonic acid ester) | 848486-23-7

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 有机磷酸及其衍生物
• 英文名称: 1,4,5,8-tetrahydro-1,4:5,8-dimethanoanthracene-9,10-bis(methylphosphonic acid ester)
• 英文别名: [(1R,5S,8R,12S)-10-[hydroxy(methyl)phosphoryl]oxy-3-pentacyclo[10.2.1.15,8.02,11.04,9]hexadeca-2,4(9),6,10,13-pentaenyl]oxy-methylphosphinic acid
• CAS: 848486-23-7
• 化学式: C₁₈H₂₀O₆P₂
• 分子量: 394.301
• InChiKey: SIOPYIOQZRAQPD-IWDIQUIJSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  26
• 可旋转键数：
  4
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.44
• 拓扑面积：
  93.1
• 氢给体数：
  2
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  1,4,5,8-tetrahydro-1,4:5,8-dimethanoanthracene-9,10-bis(methylphosphonic acid ester) 在 lithium hydroxide 作用下， 以 甲醇 为溶剂， 反应 2.0h， 以100%的产率得到bis-lithium syn-(1α,4α,5α,8α)-1,4,5,8-tetrahydro-1,4:5,8-dimethanoanthracene-9,10-bis(methylphosphonate)
  参考文献：
  名称：

  Kirsch, Michael; Talbiersky, Peter; Polkowska, Jolanta, Angewandte Chemie - International Edition, 2009, vol. 48, p. 2886 - 2890

  摘要：

  DOI：
• 作为产物：
  描述：

  在 盐酸 作用下， 以 四氢呋喃 、 正己烷 为溶剂， 以110 mg的产率得到1,4,5,8-tetrahydro-1,4:5,8-dimethanoanthracene-9,10-bis(methylphosphonic acid ester)
  参考文献：
  名称：

  N-烷基吡啶鎓盐的选择性络合：NAD +在水中的结合。

  摘要：

  提出了一类新的受体分子，其对N-烷基吡啶鎓离子和电子贫乏的芳族化合物具有高度选择性。它的关键特征是将预先组织良好的分子夹与富电子的内腔以及策略性放置的侧接双膦酸酯单酯阴离子相结合。结合位点的这种形状和排列主要在水中吸引平坦的电子贫乏芳香族化合物，主要通过pi-阳离子，pi-pi，CH-pi和疏水性相互作用将其结合，并导致其高效去溶剂化。NAD（+）和NADP，许多氧化还原酶的重要辅助因子，被新的受体分子所识别，该受体分子具有催化活性的烟酰胺位和腺嘌呤单元。甚至腺苷之类的核苷也同样被吸入夹子的腔中。通过一维和二维NMR光谱，Job图分析，等温滴定微量量热（ITC）测量以及（1）H NMR位移的量子化学计算，检查了复合物的形成和结构。新的受体分子是控制酶氧化过程和DNA化学的有前途的工具。

  DOI：

  10.1002/chem.200400603

文献信息

• Treatment of spinal cord injury or traumatic brain injury by inhibition of synuclein protein aggregation
  申请人：THE REGENTS OF THE UNIVERSITY OF CALIFORNIA

  公开号：US10918657B2

  公开（公告）日：2021-02-16

  Methods for the treatment of spinal cord injury or traumatic brain injury are provided. In certain embodiments, the methods include the use of a molecular tweezers and/or nucleobase oligomer capable of inhibiting the accumulation or aggregation of one or more amyloidogenic proteins and/or synuclein proteins. Examples of treatments that may inhibit accumulation or aggregation of one or more amyloidogenic proteins and/or synuclein proteins include treatment with a synuclein antisense nucleobase oligomer or treatment with the molecular tweezers CLR01. These treatments may improve outcomes of spinal cord surgery or traumatic brain injury, including, without limitation, neuronal survival, neuronal regeneration, and recovery of neuronal functions.

  本文提供了治疗脊髓损伤或创伤性脑损伤的方法。在某些实施方案中，这些方法包括使用能够抑制一种或多种致淀粉样蛋白和/或突触核蛋白的积累或聚集的分子镊子和/或核基寡聚体。可抑制一种或多种致淀粉样蛋白和/或突触核蛋白的积聚或聚集的治疗实例包括使用突触核蛋白反义核碱基寡聚体或使用分子镊CLR01治疗。这些治疗方法可改善脊髓手术或创伤性脑损伤的治疗效果，包括但不限于神经元存活、神经元再生和神经元功能恢复。
• Selective Complexation of N-Alkylpyridinium Salts: Recognition of NAD+ in Water
  作者：Christian Jasper、Thomas Schrader、Jens Panitzky、Frank-Gerrit Klärner

  DOI：10.1002/1521-3773(20020415)41:8<1355::aid-anie1355>3.0.co;2-6

  日期：2002.4.15
• TREATMENT OF SPINAL CORD INJURY OR TRAUMATIC BRAIN INJURY BY INHIBITION OF AMYLOIDOGENIC PROTEINS AND SYNUCLEIN PROTEIN ACCUMULATION OR AGGREGATION
  申请人：THE REGENTS OF THE UNIVERSITY OF CALIFORNIA

  公开号：US20150202222A1

  公开（公告）日：2015-07-23

  Methods for the treatment of spinal cord injury or traumatic brain injury are provided. In certain embodiments, the methods include the use of a molecular tweezers and/or nucleobase oligomer capable of inhibiting the accumulation or aggregation of one or more amyloidogenic proteins and/or synuclein proteins. Examples of treatments that may inhibit accumulation or aggregation of one or more amyloidogenic proteins and/or synuclein proteins include treatment with a synuclein antisense nucleobase oligomer or treatment with the molecular tweezers CLR01. These treatments may improve outcomes of spinal cord surgery or traumatic brain injury, including, without limitation, neuronal survival, neuronal regeneration, and recovery of neuronal functions.
• INHIBITION OF LIPOFUSCIN AGGREGATION BY MOLECULAR TWEEZERS
  申请人：The Regents of the University of California

  公开号：US20210069217A1

  公开（公告）日：2021-03-11

  In various embodiments methods for the treatment and/or prophylaxis of lipofuscin-related disorders are provided. In certain embodiments the methods involve administration of an effective amount of a molecular tweezers to a subject in need thereof.
• NEW MOLECULAR TWEEZERS AGAINST NEUROLOGICAL DISORDERS AND VIRAL INFECTIONS
  申请人：The Regents of the University of California

  公开号：US20210122771A1

  公开（公告）日：2021-04-29

  In various embodiments new molecular tweezers compounds are provided. The compounds described herein (e.g., molecular tweezers) are believed to be useful for inhibiting protein aggregation (or disaggregating aggregated proteins). In certain embodiments the compounds described herein (e.g., molecular tweezers) are believed to be useful in the treatment of pathologies characterized by protein aggregation (e.g., amyloidopathies), and/or in the treatment of brain or spinal cord damage associated with acute trauma, stroke, and the like, and/or in the treatment of lysosomal storage diseases, and/or in the treatment of lipofuscin-related disorders, and in various viral infections.